Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Heron Therapeutics (HRTX) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Heron Therapeutics (HRTX) over the last 12 years, with Q3 2025 value amounting to 45.78%.

  • Heron Therapeutics' EBITDA Margin fell 311500.0% to 45.78% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.78%, marking a year-over-year increase of 114900.0%. This contributed to the annual value of 9.41% for FY2024, which is 775900.0% up from last year.
  • Per Heron Therapeutics' latest filing, its EBITDA Margin stood at 45.78% for Q3 2025, which was down 311500.0% from 6.41% recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' EBITDA Margin registered a high of 8.92% during Q4 2024, and its lowest value of 272.37% during Q1 2022.
  • Over the past 5 years, Heron Therapeutics' median EBITDA Margin value was 79.54% (recorded in 2023), while the average stood at 114.02%.
  • As far as peak fluctuations go, Heron Therapeutics' EBITDA Margin crashed by -629000bps in 2021, and later skyrocketed by 1985300bps in 2022.
  • Quarter analysis of 5 years shows Heron Therapeutics' EBITDA Margin stood at 264.58% in 2021, then skyrocketed by 75bps to 66.04% in 2022, then surged by 53bps to 31.29% in 2023, then surged by 128bps to 8.92% in 2024, then plummeted by -613bps to 45.78% in 2025.
  • Its EBITDA Margin was 45.78% in Q3 2025, compared to 6.41% in Q2 2025 and 6.74% in Q1 2025.